Gordan, L.N.; Ray, D.; Ijioma, S.C.; Dranitsaris, G.; Warner, A.; Heritage, T.; Fink, M.; Wenk, D.; Chadwick, P.; Khrystolubova, N.;
et al. Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor. Curr. Oncol. 2024, 31, 501-510.
https://doi.org/10.3390/curroncol31010034
AMA Style
Gordan LN, Ray D, Ijioma SC, Dranitsaris G, Warner A, Heritage T, Fink M, Wenk D, Chadwick P, Khrystolubova N,
et al. Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor. Current Oncology. 2024; 31(1):501-510.
https://doi.org/10.3390/curroncol31010034
Chicago/Turabian Style
Gordan, Lucio N., David Ray, Stephen C. Ijioma, George Dranitsaris, Amanda Warner, Trevor Heritage, Matthew Fink, David Wenk, Paul Chadwick, Natasha Khrystolubova,
and et al. 2024. "Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor" Current Oncology 31, no. 1: 501-510.
https://doi.org/10.3390/curroncol31010034
APA Style
Gordan, L. N., Ray, D., Ijioma, S. C., Dranitsaris, G., Warner, A., Heritage, T., Fink, M., Wenk, D., Chadwick, P., Khrystolubova, N., & Peles, S.
(2024). Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor. Current Oncology, 31(1), 501-510.
https://doi.org/10.3390/curroncol31010034
